Progress in Pediatric Cardiology
Volume 25, Issue 2 , Pages 167-176 , September 2008

Assessment of atherosclerotic cardiovascular risk and management of dyslipidemia in obese children

References 

  1. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999–2000. JAMA. 2002;288(14):1728–1732
  2. Kavey RW, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K. American Heart Association Guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation. 2003;107(11):1562–1566
  3. Must A, Jacques PF, Dallal GE, Bajema CJ, Dietz WH. Long-term morbidity and mortality of overweight adolescents. A follow-up of the Harvard Growth Study of 1922–1935. N Engl J Med. 1992;327(19):1350–1355
  4. Baker JL, Olsen LW, Sorensen TI. Childhood body-mass index and the risk of coronary heart disease in adulthood. N Engl J Med. 2007;357(23):2329–2337
  5. Bibbins-Domingo K, Coxson P, Pletcher MJ, Lightwood J, Goldman L. Adolescent overweight and future adult coronary heart disease. N Engl J Med. 2007;357(23):2371–2379
  6. Lorch SM, Sharkey A. Myocardial velocity, strain and strain rate abnormalities in healthy obese children. J Cardiometab Syndr. 2007;2(1):30–34
  7. Newman WP, Freedman DS, Voors AW, et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. N Engl J Med. 1986;314(3):138–144
  8. Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine Study. Circulation. 2001;104(23):2815–2819
  9. Celermajer DS. Endothelial dysfunction: does it matter? Is it reversible?. J Am Coll Cardiol. 1997;30(2):325–333
  10. Urbina EM, Brinton TJ, Elkasabany A, Berenson GS. Brachial artery distensibility and relation to cardiovascular risk factors in healthy young adults (The Bogalusa Heart Study). Am J Cardiol. 2002;89(8):946–951
  11. de Jongh S, Lilien MR, Bakker HD, Hutten BA, Kastelein JJ, Stroes ES. Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia. Atherosclerosis. 2002;163(1):193–197
  12. Kavey RW, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association expert panel on population and prevention science; the councils on cardiovascular disease in the young, epidemiology and prevention, nutrition, physical activity and metabolism, high blood pressure research, cardiovascular nursing, and the kidney in heart disease; and the interdisciplinary working group on quality of care and outcomes research: endorsed by the American Academy of Pediatrics. Circulation. 2006;114(24):2710–2738
  13. Pinto NM, Marino BS, Wernovsky G, et al. Obesity is a common comorbidity in children with congenital and acquired heart disease. Pediatrics. 2007;120(5):e1157–e1164
  14. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299–308
  15. Rocchini AP, Katch V, Kveselis D, et al. Insulin and renal sodium retention in obese adolescents. Hypertension. 1989;14(4):367–374
  16. Rocchini AP, Key J, Bondie D, et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med. 1989;321(9):580–585
  17. Laakso M, Barrett-Connor E. Asymptomatic hyperglycemia is associated with lipid and lipoprotein changes favoring atherosclerosis. Arteriosclerosis. 1989;9(5):665–672
  18. Garg A, Helderman JH, Koffler M, Ayuso R, Rosenstock J, Raskin P. Relationship between lipoprotein levels and in vivo insulin action in normal young white men. Metabolism. 1988;37(10):982–987
  19. Stalder M, Pometta D, Suenram A. Relationship between plasma insulin levels and high density lipoprotein cholesterol levels in healthy men. Diabetologia. 1981;21(6):544–548
  20. Pykalisto OJ, Smith PH, Brunzell JD. Determinants of human adipose tissue lipoprotein lipase. Effect of diabetes and obesity on basal- and diet-induced activity. J Clin Invest. 1975;56(5):1108–1117
  21. Golay A, Zech L, Shi MZ, Chiou YA, Reaven GM, Chen YD. High density lipoprotein (HDL) metabolism in noninsulin-dependent diabetes mellitus: measurement of HDL turnover using tritiated HDL. J Clin Endocrinol Metab. 1987;65(3):512–518
  22. Singhal A, Farrooqi IS, Cole TJ, et al. Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease?. Circulation. 2002;106(15):1919–1924
  23. Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the committee on vascular lesions of the council on arteriosclerosis. American Heart Association. Circulation. 1994;89(5):2462–2478
  24. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the committee on vascular lesions of the council on arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol. 1995;15(9):1512–1531
  25. Enos WF, Holmes RH, Beyer J. Coronary disease among United States soldiers killed in action in Korea; preliminary report. JAMA. 1953;152(12):1090–1093
  26. McNamara JJ, Molot MA, Stremple JF, Cutting RT. Coronary artery disease in combat casualities in Vietnam. JAMA. 1971;216(7):1185–1187
  27. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA. 1990;264(23):3018–3024
  28. McGill HC, McMahan CA, Zieske AW, et al. Association of coronary heart disease risk factors with microscopic qualities of coronary atherosclerosis in youth. Circulation. 2000;102(4):374–379
  29. McGill HC, McMahan CA, Herderick EE, et al. Obesity accelerates progression of atherosclerosis in young men. Circulation. 2002;105(23):2712–2718
  30. Berenson GS, Srinivasan SR, Bao W, Newman WP, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998;338(23):1650–1656111
  31. Freedman DS, Dietz WH, Tang R, et al. The relation of obesity throughout life to carotid intima-media thickness in adulthood: the Bogalusa Heart Study. Int J Obes Relat Metab Disord. 2004;28(1):159–166
  32. Steinberger J, Moran A, Hong CP, Jacobs DR, Sinaiko AR. Adiposity in childhood predicts obesity and insulin resistance in young adulthood. J Pediatr. 2001;138(4):469–473
  33. Sinaiko AR, Jacobs DR, Steinberger J, et al. Insulin resistance syndrome in childhood: associations of the euglycemic insulin clamp and fasting insulin with fatness and other risk factors. J Pediatr. 2001;139(5):700–707
  34. American Academy of Pediatrics . National Cholesterol Education Program: report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics. 1992;89(3):525–584
  35. McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents. A scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation. 2007;115(14):1948–1967
  36. Groner JA, Joshi M, Baurer JA. Pediatric precursors of adult cardiovascular disease: noninvasive assessment of early vascular changes in children and adolescents. Pediatrics. 2006;118(4):1683–1691
  37. Raitakari OT. Arterial abnormalities in children with familial hypercholesterolemia. Lancet. 2004;363(9406):342–343
  38. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 1995;26:1235–1241
  39. Meyer AA, Kundt G, Lenschow U, Schuff-Werner P, Kienast W. Improvement of early vascular changes and cardiovascular risk factors in obese children after a six-month exercise program. J Am Coll Cardiol. 2006;48(9):1865–1870
  40. de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol. 2002;40(12):2117–2121
  41. Bots ML, Dijk JM, Oren A, Grobbee DE. Carotid intima-media thickness, arterial stiffness and risk of cardiovascular disease: current evidence. J Hypertens. 2002;20(12):2317–2325
  42. London G, Cohn J. Prognostic application of arterial stiffness: task forces. Am J Hypertens. 2002;15(8):754–758
  43. Whincup PH, Gilg JA, Donald AE, et al. Arterial distensibility in adolescents: the influence of adiposity, the metabolic syndrome, and classic risk factors. Circulation. 2005;112(12):1789–1797
  44. Iannuzzi A, Licenziati MR, Acampora C, et al. Carotid artery stiffness in obese children with the metabolic syndrome. Am J Cardiol. 2006;97(4):528–531
  45. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) study, 1987–1993. Am J Epidemiol. 1997;146(6):483–494
  46. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults: Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340(1):14–22
  47. Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim intima-media thickness consensus. Cerebrovasc Dis. 2004;18(4):346–349
  48. Wunsch R, de Sousa G, Toschke AM, Reinehr T. Intima-media thickness in obese children before and after weight loss. Pediatrics. 2006;118(6):2334–2340
  49. Wiegman A, de Groot E, Hutten BA, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolemia. Lancet. 2004;363(9406):369–370
  50. Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004;292(3):331–337
  51. Charakida M, Donald AE, Terese M, et al. Endothelial dysfunction in childhood infection. Circulation. 2005;111(13):1660–1665
  52. Lavi S, Yang EH, Prasad A, et al. The interaction between coronary endothelial dysfunction, local oxidative stress, and endogenous nitric oxide in humans. Hypertension. 2008;51(1):127–133
  53. Palm F, Onozato ML, Luo Z, Wilcox CS. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol, Heart Circ Physiol. 2007;293(6):H3227–3245
  54. Pepys MB, Hirscfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805–1812
  55. Jarvisalo MJ, Harmoinen A, Hakanen M, et al. Elevated serum C-reactive protein levels and early arterial changes in healthy children. Arterioscler Thromb Vasc Biol. 2002;22(8):1323–1328
  56. deSimone G, Devereux RG, Daniels SR, et al. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol. 1995;25(5):1056–1062
  57. Ippisch HM, Inge TH, Daniels SR, et al. Reversibility of cardiac abnormalities in morbidly obese adolescents. J Am Coll Cardiol. 2008;51:1342–1348
  58. Arad Y. Beyond traditional risk factor analysis for coronary artery disease: the case for coronary artery calcium assessment with electron beam computed tomography. Prev Cardiol. 2002;5(2):62–67
  59. Gylling H, Siimes MA, Miettinen TA. Sitostanolol ester margarine in dietary treatment of children with familial hypercholesterolemia. J Lipid Res. 1995;36(8):1807–1812
  60. de Jongh S, Vissers MN, Rol P, Bakker HD, Kastelein JJ, Stroes ES. Plant sterols lower LDL cholesterol without improving endothelial function in prepubertal children with familial hypercholesterolemia. J Inherit Metab Dis. 2003;26(4):343–351
  61. Jakulj L, Vissers MN, Rodenburg J, Wiegman A, Trip MD, Kastelein JJ. Plant sterols do not restore endothelial function in pre-pubertal children with familial hypercholesterolemia despite reduction of low density lipoprotein levels. J Pediatr. 2006;148(4):495–500
  62. Albert CM, Campos H, Stampfer MJ, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med. 2002;346(15):1113–1118
  63. London B, Albert C, Anderson ME, et al. Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and Office Of Dietary Supplements Omega-3 Fatty Acids and their Role in Cardiac Arrhythmogenesis Workshop. Circulation. 2007;116(10):e320–e335
  64. Engler MM, Engler MB, Malloy M, et al. Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: results from the EARLY study. Int J Clin Pharmacol Ther. 2004;42(12):672–679
  65. Moreno LA, Tresaco B, Bueno G, et al. Psyllium fibre and the metabolic control of obese children and adolescents. J Physiol Biochem. 2003;59(3):235–242
  66. Dennison BA, Levine DM. Randomized, double-blind, placebo-controlled, two-period, crossover clinical trial of psyllium fiber in children with hypercholesterolemia. J Pediatr. 1993;123(1):24–29
  67. Mietus-Snyder M, Malloy MJ. Endothelial dysfunction occurs in children with two genetic hyperlipidemias: improvement with antioxidant vitamin therapy. J Pediatr. 1998;133(1):35–40
  68. Engler MM, Engler MB, Malloy MY, et al. Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation. 2003;108(9):1059–1063
  69. Steinbeck KS. The importance of physical activity in the prevention of overweight and obesity in childhood: a review and an opinion. Obes Rev. 2001;2(2):117–130
  70. Tolfrey K, Jones AM, Campbell IG. The effect of aerobic exercise training on the lipid–lipoprotein profile of children and adolescents. Sports Med. 2000;29(2):99–112
  71. Daniels SR. Exercise and lipid abnormalities. Pediatr Cardiol. 1999;20(1):71–77
  72. Katzmarzyk PT, Malina RM, Bouchard C. Physical activity, physical fitness, and coronary heart disease risk factors in youth: the Quebec Family Study. Prev Med. 1999;29(6pt 1):555–562
  73. Tolfrey K, Campbell IG, Jones AM. Selected predictor variables and the lipid–lipoprotein profile of prepubertal girls and boys. Med Sci Sports Exerc. 1999;31(11):1550–1557
  74. Tolfrey K, Campbell IG, Batterham AM. Exercise training induced alterations in prepubertal children's lipid–lipoprotein profile. Med Sci Sports Exerc. 1998;30(12):1684–1692
  75. Janz KF, Dawson JD, Mahoney LT. Increases in physical fitness during childhood improve cardiovascular health during adolescence: the Muscatine Study. Int J Sports Med. 2002;23(suppl 1):S15–21
  76. Kemper HC, Twisk JW, Koppes LL, van Mechelen W, Post GB. A 15-year physical activity pattern is positively related to aerobic fitness in young males and females (13-27 years). Eur J Appl Physiol. 2001;84(5):395–402
  77. McCrindle BW. Drug therapy of hyperlipidemia. Prog Pediatr Cardiol. 2003;17:141–150
  78. Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr. 1996;129(1):42–49
  79. Kwiterovich PO. State-of-the-art update and review: clinical trials of lipid lowering agents. Am J Cardiol. 1998;82(12A):3U–17U
  80. Lambert M, Lupien PJ, Gagné C, et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. Pediatrics. 1996;97(5):619–628
  81. Stein EA, Illingworth DR, Kwiterovich PO, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA. 1999;281(2):137–144
  82. Ducobu J, Brasseur D, Chaudron JM, et al. Simvastatin use in children. Lancet. 1992;339(8807):1488
  83. de Jongh S, Ose L, Szamosi T, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation. 2002;106(17):2231–2237
  84. Knipscheer HC, Boelen CC, Kastelein JJ, et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res. 1996;39(5):867–871
  85. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr. 2003;143(1):74–80
  86. van der Graaf A, Nierman MC, Firth JC, Wolmarans KH, Marais AD, de Groot E. Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolaemia. Acta Pediatr. 2006;95(11):1461–1466
  87. Fichtlscherer S, Schmidt-Lucke C, Bojunga S, et al. Differential effects of short-term lipid lowering with ezetemibe and statins on endothelial function in patients with CAD: clinical evidence for “pleiotropic” functions of statin therapy. Eur Heart J. 2006;27(10):1182–1190
  88. Gagne C, et al. Efficacy and safety of ezetemibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002;105(21):2469–2475
  89. Colletti RB, Neufeld EJ, Roff NK, McAuliffe TL, Baker AL, Newburger JW. Niacin treatment of hypercholesterolemia in children. Pediatrics. 1993;92(1):78–82
  90. Wheeler KA, West RJ, Lloyd JK, Barley J. Double blind trial of bezafibrate in familial hypercholesterolemia. Arch Dis Child. 1985;60(1):34–37
  91. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62(5):707–714
  92. Davidson MH, Mckenney JM, Shear CL, Revkin JH. Efficacy and safety of Torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol. 2006;48(9):1774–1781
  93. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism?. Arterioscler Thromb Vasc Biol. 2007;27(2):257–260

PII: S1058-9813(08)00040-4

doi: 10.1016/j.ppedcard.2008.05.005

Progress in Pediatric Cardiology
Volume 25, Issue 2 , Pages 167-176 , September 2008

Article Tools

* Image Usage & Resolution